Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

Regeneron stock recovered and closed higher Monday after the drugmaker preannounced light sales of a high-dose version of its blockbuster eye drug, Eylea. Please watch the video at Investors.com ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Regeneron stock jumped Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea. Please watch the video at Investors.com - Biotech Stocks Are ...

Two one-shot doses of 4D-150 are being tested in the study and compared to Eylea. The high dose of the gene therapy – which is designed to express both aflibercept and an RNA interference (RNAi ...

They are currently working on a higher-dose version of the medicine to compete with Eylea HD. Teva Pharmaceutical Industries shares climbed about 3% Tuesday morning following the release ...

Regular dose Eylea sales in the US were $1.2 billion, or an 11% year-on-year decline, while Eylea high-dose sales in the US were $305 million, or 148% year-on-year growth. Although Roche’s ...

Despite lower-than-expected sales for Eylea High Dose, the drug used to treat eye diseases, sales of Eylea 2mg exceeded expectations. Jefferies also maintained a Buy rating, albeit with a revised ...

The Eylea franchise -- including a high-dose (HD) formulation that first earned approval in 2023 -- is facing stiff competition, biosimilar and otherwise. The medicine's sales growth has slowed ...